Natixis Advisors LLC Purchases 22,267 Shares of Elevance Health, Inc. $ELV

Natixis Advisors LLC grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 9.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 267,062 shares of the company’s stock after purchasing an additional 22,267 shares during the period. Natixis Advisors LLC owned about 0.12% of Elevance Health worth $93,619,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. 3Chopt Investment Partners LLC bought a new stake in shares of Elevance Health in the 4th quarter valued at about $206,000. Root Financial Partners LLC lifted its stake in shares of Elevance Health by 112.5% in the 4th quarter. Root Financial Partners LLC now owns 136 shares of the company’s stock valued at $48,000 after acquiring an additional 72 shares during the last quarter. Mawer Investment Management Ltd. lifted its stake in shares of Elevance Health by 10.9% in the 4th quarter. Mawer Investment Management Ltd. now owns 207,095 shares of the company’s stock valued at $72,597,000 after acquiring an additional 20,438 shares during the last quarter. GW Henssler & Associates Ltd. bought a new stake in shares of Elevance Health in the 4th quarter valued at about $217,000. Finally, New Mexico Educational Retirement Board lifted its stake in shares of Elevance Health by 3.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 10,646 shares of the company’s stock valued at $3,732,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 3.6%

ELV stock opened at $388.33 on Wednesday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The business’s 50 day moving average price is $345.97 and its two-hundred day moving average price is $339.77. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market capitalization of $84.33 billion, a price-to-earnings ratio of 16.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the prior year, the business earned $11.97 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts forecast that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is 29.26%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ELV shares. Truist Financial boosted their target price on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research note on Monday. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and boosted their target price for the company from $405.00 to $435.00 in a research note on Wednesday, April 29th. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and boosted their target price for the company from $363.00 to $498.00 in a research note on Wednesday, May 20th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $407.05.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.